Christopher Scarlett

Since his appointment to the University of Newcastle Central Coast Campus in 2012, Professor Scarlett has commissioned a unique facility in Australia identifying novel anti-pancreatic cancer (PC) therapeutic agents, derived synthetically and from natural products, as part of a PC translational treatment pipeline.

Through his links with the Kinghorn Cancer Centre, Garvan Institute of Medical Research, HMRI, The Lowy Cancer Research Centre and the University of Newcastle, Professor Scarlett created a dedicated centre for the development of novel therapeutic agents based on a rationally designed strategy targeting phenotypes of PC that are non-responsive to conventional therapies. This has the potential to have a profound impact not only on future PC treatments but to serve as a model for developing new therapeutic interventions in other cancers.

In building this research program, and with the assistance of a Ramaciotti Foundation Establishment Grant and University of Newcastle (UoN) seed funding, Professor Scarlett established and continues to lead the Pancreatic Cancer Research Group (PCRG). This positioned a critical mass of researchers with interests in pancreatic cancer, not seen before at UoN, with complementary skill sets in cancer biology, medicinal chemistry, synthetic chemistry, and natural product chemistry within his laboratory. This group is aligned with other key research teams locally and internationally and has ready access to key infrastructure (natural product/medicinal chemistry, cancer biology, pre-clinical models of PC) to develop a PC translational treatment pipeline.

Professor Scarlett has forged productive national and international collaborations to ensure that the research output generated internally is extended significantly and that these studies are disseminated in international top-tier publications.

Internationally the team’s partners involved in natural product drug discovery include the National Institute of Medicinal Material (NIMM) Hanoi, Nha Trang University, and the Hanoi University of Agriculture (HUA), providing us with compounds to assess in vitro models of PC; as well as collaborative ties with The University of Glasgow Translational Research Centre and the National Cancer Institute, National Institutes of Health.

He has been awarded project grant funding through the Priority-driven Collaborative Cancer Research Scheme, co-funded by Cancer Australia and the Cure Cancer Australia Foundation (CIA; 2012-1013). He is also a Co-Investigator on a successful NHMRC program grant ($11,128,320; 2009-2013), and a Co-Chief Investigator on successful project grants through the NHMRC (CI-B; 2011-2013) and The Cancer Council NSW (CI-C; 2010-2012) in collaboration with Dr Tao Liu at the Children’s Cancer Institute Australia.